Table 2.

Positive Effects of Mavacamten on Biomarkers, Diastolic Function and Left Ventricular Hypertrophy Observed in the VALOR-HCM Trial

	NT-proBNP	Troponin I	E/e Ratio	LV Mass Index	Left Atrial Volume Index
Placebo vs mavacamten group (week 16-32)	−451 ng/L (95% CI: −581 to −298)	−6.8 ng/L (95% CI: −8.5 to −4.3)	−2.6 (95% CI: −4.6 to −0.7)	−10.8 g/m2 (95% CI: −16.1 to −5.5)	−5.5 ml/m2 (95% CI: −8.3 to −2.7)
Mavacamten group (baseline to week 32)	−417 ng/L (95% CI: −706 to −186)	−7.4 ng/L (95% CI: −11.1 to −4.8)	−3.3 (95% CI: −4.9 to −1.8)	−13.0 g/m2 (95% CI: −18.5 to −7.5)	−6.8 ml/m2 (95% CI: −9.4 to −4.3)

LV = left ventricular.